Skip to content

{ Tag Archives } Skin Lesions

Phase III REGION-I Study Shows PEP005 (ingenol Mebutate) Gel 0.05% May Reduce Pre-Cancerous Skin Lesions In Patients With Actinic Keratosis

Specialty pharmaceutical company LEO Pharma announced that findings from a Phase III study evaluating PEP005 (ingenol mebutate) Gel 0.05% to treat actinic keratosis (AK), a common pre-cursor to skin cancer, were presented at the 68th Annual Meeting of the American Academy of Dermatology (AAD) (Scientific Session Poster Discussion: P105)…

Bookmark and Share Also tagged , , , , , , ,

Study Shows Twice Weekly Etanercept (Enbrel) Clears Psoriasis Lesions More Quickly Than Once Weekly Treatment

Initial treatment with twice weekly etanercept (Enbrel), a tumour necrosis factor antagonist, achieves more rapid clearance of skin lesions than once weekly treatment in patients with active psoriasis and psoriatic arthritis, according to results from the PRESTA study reported recently in the British Medical Journal…

Bookmark and Share Also tagged , , , , , , , , , , ,

New Device Enables Early Detection Of Cancerous Skin Tumors — Ben Gurion U.

Researchers at Ben-Gurion University of the Negev are developing a new device that detects cancerous skin tumors, including melanomas that aren’t visible to the naked eye. During initial testing, the OSPI instrument (Optical Spectro-Polarimetric Imaging) revealed new textures of lesions that have never been seen before – including melanoma in patients who [...]

Bookmark and Share Also tagged , , , , , , , ,

Heparin Can Cause Skin Lesions

Heparin, a commonly used anticoagulant, can cause skin lesions, reports a study http://www.cmaj.ca/press/cmaj081729.pdf in CMAJ (Canadian Medical Association Journal). Skin lesions caused by heparin may indicate the presence of a life-threatening decrease in the number of platelets, a condition called “heparin-induced thrombocytopenia” or, in most cases, a self-limiting, allergic skin reaction.

Bookmark and Share Also tagged , , , , , , , , , ,

BioLineRx Initiates Phase I/II Trial Of BL-5010, A Novel Formulation For The Non Surgical Removal Of Skin Lesions

BioLineRx, a drug development company with products in advanced clinical and pre-clinical testing, today announced the initiation of a Phase I/II clinical trial aimed at assessing the safety and efficacy of BL-5010, a novel formulation for the non surgical removal of skin lesions. The open-label, single arm trial will be conducted in 60 [...]

Bookmark and Share Also tagged , , , , , , , ,

Study Evaluates Types Of Skin Diseases Among Military Personnel Who Were Evacuated From Combat Zones

Dermatitis, benign moles, hives and cancerous skin lesions are among the most common diagnoses among military personnel who were evacuated from combat zones for ill-defined dermatologic diseases, according to a report in the February issue of Archives of Dermatology, one of the JAMA/Archives journals.

Bookmark and Share Also tagged , , , , , , , ,

Electro-Optical Sciences Announces Positive Top-Line Results From Landmark MelaFind(R) Pivotal Trial

Electro-Optical Sciences, Inc. (”EOS”) (NASDAQ: MELA) announced positive top-line results of its pivotal trial of MelaFind, a non-invasive, point-of-care instrument to assist in the early detection of melanoma, the deadliest form of skin cancer. The blinded study, [...]

Bookmark and Share Also tagged , , , , , , , ,

Ustekinumab Reduces Symptoms Of Psoriatic Arthritis And Diminishes Skin Lesions Compared With Placebo

The drug ustekinumab reduces symptoms of psoriatic arthritis (PA) and diminishes skin lesions compared with placebo. These are the conclusions of an Article published Online First and in an upcoming edition of The Lancet, written by Dr Alice Gottlieb, Department of Dermatology, Tufts Medical Center, Boston, MA, USA, and colleagues. PA is a [...]

Bookmark and Share Also tagged , , , , , , , , , , ,